Epidermal growth factor receptor inhibitors (EGFR inhibitors) represent a targeted therapy used for patients with advanced CRC and encompass two principal categories: anti-EGFR monoclonal antibodies and tyrosine kinase inhibitors [3]. The gene discussed is EGFR; the disease is colorectal carcinoma.